Completed
There is broad recognition of the need to address the development and spread of antimicrobial resistance (AMR). A global, systematic analysis estimates that AMR infections lead to 1.27- 4.95 million deaths per year, and resistant bacterial infections are now a leading cause of neonatal mortality worldwide. However, a critical question remains on whether the impact of AMR is being fully understood and quantified throughout medical practice and everyday life, from cancer treatment to food production. Discussions at this workshop will cover current clinical and economic burdens of AMR, data availability and analytical methods, and potential strategies to incorporate these insights.
Featured publication
Workshop_in_brief
·2024
Antimicrobial resistance (AMR) is linked to millions of deaths globally each year. As an evolving public health threat, there is a need to further develop methods to quantify AMR's burden within medical practice and other sectors like food production. The National Academies Forum on Microbial Threat...
View details
Description
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize a public workshop to explore the current burden of antimicrobial resistance and discuss opportunities for future policies in the context of new scientific innovations and potential disruptions from proposed and pilot incentive mechanisms. The workshop will feature invited presentations and discussions that may consider topics, including:
- Assessment of the current clinical and economic burden of antimicrobial resistance, including an overview of emerging challenges, efforts to improve data availability and analytical methods, and examination of the impact antimicrobials have as the foundation of modern medicine and their role in strengthening public health preparedness and response to health emergencies.
- Highlights in scientific progress in developing new therapeutics to address antimicrobial resistant pathogens, including discussions around technical challenges, financial costs, and market viability.
- Innovative incentive models and policy options (proposed or pilot programs) that address antimicrobial resistance, including discussions around: barriers for implementation and how these barriers may be overcome, how incentives mechanisms can be adapted to national or regional contexts, how these approaches might complement each other, and considerations of roll out of and sustainable access to novel antimicrobial agents.
The planning committee will organize the workshop, develop the agenda, select speakers and discussants, and moderate or identify moderators for the discussions. A proceedings summarizing the presentations and discussions held during this workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Contributors
Sponsors
American Society of Tropical Medicine and Hygiene
Burroughs Wellcome Fund
Centers for Disease Control and Prevention (CDC)
Department of Veterans Affairs
EcoHealth Alliance
Infectious Diseases Society of America
Johnson & Johnson
Merck & Co., Inc.
National Institute of Allergy and Infectious Diseases
New Venture Fund
Other, Federal
Private: For Profit
Private: Non Profit
Rockefeller-Foundation
Sanofi
Society of Infectious Diseases Pharmacists
Uniformed Services University of the Health Sciences
United States Agency for International Development
Staff
Julie Liao
Lead
Julie Pavlin
Liz Ashby
Claire Biffl
Taylor Windmiller